Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel coronavirus SARS-CoV-2 mRNA vaccines and preparation method and application thereof

A sars-cov-2, sequence technology, applied in the fields of biomedicine and virology, can solve the problem of lack of specific drugs and vaccines, and achieve the effect of improving immune protection, high yield and reducing immunogenicity

Active Publication Date: 2021-07-23
INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
View PDF5 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, symptomatic and supportive treatments are mainly used in clinical practice, and there are no specific drugs and vaccines.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel coronavirus SARS-CoV-2 mRNA vaccines and preparation method and application thereof
  • Novel coronavirus SARS-CoV-2 mRNA vaccines and preparation method and application thereof
  • Novel coronavirus SARS-CoV-2 mRNA vaccines and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Embodiment 1: mRNA vaccine preparation

[0082] (1) Acquisition of target genes: The full-length amino acid sequences of SARS-CoV-2 receptor binding domain RBD, spike protein S1 subunit, and spike protein S were obtained from Genebank MN908947. After codon optimization, the nucleic acid sequences are as follows: Shown in SEQ ID NO: 2, 6 and 8, synthesized by Beijing Qingke Xinye Biotechnology Co., Ltd. and respectively cloned into the mRNA transcription template pHRNT vector (for example, purchased from Beijing Qingke Xinye Biotechnology Co., Ltd.) ( figure 1 ), obtain mRNA transcription template plasmid pHRNT-RBD, pHRNT-S1 and pHRNT-S ( figure 2 ).

[0083] (2) mRNA transcription

[0084] Restriction endonuclease BamHI was used to linearize the mRNA transcription templates pHRNT-RBD, pHRNT-S1 and pHRNT-S respectively, and run agarose gel electrophoresis ( image 3 ), to confirm whether the linearization is complete, and then use the gel extraction kit to recover th...

Embodiment 2

[0107] Example 2: Evaluation of Vaccine-Induced Humoral Immune Response

[0108] Divide 36 female BALB / c mice aged 6-8 weeks into 6 groups, 6 in each group, and inject placebo intramuscularly (the packaging method is the same as that of the vaccine group but lipid nanoparticles coated with polycytidylic acid, in which polycytidylic acid Cytidylic acid was purchased from Sigma), RBD (0.3 μg, 2 μg and 15 μg), S1 (15 μg) or S (15 μg) mRNA vaccine, and the blood was collected at the 4th week after immunization, and the serum was separated at 4°C and sterilized at 56°C Store at -80°C for 30 minutes before use.

[0109] (1) Determination of antigen-specific antibody titer

[0110] Dilute the SARS-CoV-2S extracellular segment protein with ELISA coating solution to 1 μg / ml, add 100 μl to each well of a 96-well plate, and place overnight at 4°C. The next day, the ELISA plate was closed, and the mouse serum was diluted in a 2-fold gradient, added to the ELISA plate and incubated at 37...

Embodiment 3

[0123] Example 3: Evaluation of Vaccine-Induced Cellular Immune Response

[0124] Divide 12 female C57BL / 6 mice aged 6-8 weeks into 2 groups, 6 mice in each group, inject placebo and RBD (15 μg) intramuscularly, and euthanize the mice at the 4th week after immunization, and take the spleen Placed in pre-cooled 1640 medium. Put the 40μm sieve on the 50ml centrifuge tube, use a 5ml syringe to grind the spleen, add 1640 medium to drop the cells into the 50ml tube, and filter out impurities and large cell clusters. Transfer all the cells to a 15ml centrifuge tube, collect the cells by centrifugation at 2000 rpm at room temperature, add 12ml of 1640 medium to wash again, and centrifuge again to collect the cells. Add 4ml of erythrocyte lysate, suspend the cells, place at room temperature for 5-10 minutes, then add 8ml of 1640 medium, collect the cells by centrifugation, add 12ml of 1640 medium to wash once, and centrifuge again to collect the cells. Add 10ml of 1640 medium to sus...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides novel coronavirus SARS-CoV-2mRNA vaccines and a preparation method and application thereof. The invention provides three mRNA vaccines, namely RBD, S1 and S vaccines. The RBD vaccine disclosed by the invention can induce a high-titer antigen-specific IgG antibody and a virus neutralization antibody after immunization with one dose, the high-titer neutralization antibody can be maintained for at least 26 weeks, and remarkable immune protection can be provided for human ACE2 transgenic mice in serum adoptive transfer protection experiments. The RBD and S vaccine disclosed by the invention can induce immune protection capable of completely resisting SARS-CoV-2 virus infection in the human ACE2 transgenic mice after immunization with two doses. A large number of experimental results show that the mRNA vaccine provided by the invention has good immunogenicity, forms powerful immune protection after immunizing an organism, and has a huge development potential.

Description

technical field [0001] The invention relates to the fields of biomedicine and virology, in particular to a novel coronavirus SARS-CoV-2 mRNA vaccine and its preparation method and application. Background technique [0002] At present, the main source of infection of SARS-CoV-2 is patients infected with the new coronavirus, but asymptomatic patients may also become the source of infection. The virus is mainly transmitted through respiratory droplets and contact. The transmission routes such as aerosol and digestive tract have yet to be clarified. There is no evidence that it can be transmitted vertically from mother to child, and the incubation period is 1-14 days, most of which are 3-7 days. Most patients have fever, fatigue, and dry cough, and a few patients have symptoms such as nasal congestion, runny nose, sore throat, and diarrhea. Severe patients often have dyspnea or hypoxemia within 1 or 2 weeks of onset. Rapid progression to acute respiratory distress syndrome, sep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/50A61K39/215A61P31/14A61K9/51A61K47/24A61K47/28
CPCC07K14/005A61K39/12A61K9/5146A61K9/5123A61P31/14C12N2770/20022C12N2310/335C12N2770/20034A61K2039/53
Inventor 严景华黄庆瑞马素芳高福
Owner INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com